Troels Jordansen | Chief Executive Officer
Glycostem Therapeutics

Troels Jordansen, Chief Executive Officer, Glycostem Therapeutics

Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different cellular therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd and British Azellon Ltd. where he was a co-founder. Troels roles have covered sales, marketing and general management and the last 15 years as Managing Director and/or Chairman for private and public listed companies. Troels has been part of award winning management teams raising over €150 million. Troels became Chairman of Glycostem in January 2014 and CEO in July 2016.

Appearances:



Conference Day 2 - Wednesday 1st April 2020 @ 14:00

Building your own closed manufacturing system

  • Are CMOs really needed?
  • What happens to IP when working with CMOs?
  • Is in-house GMP production really an option?

Conference Day 2 - Wednesday 1st April 2020 @ 15:20

World’s first off-the-shelf NK cellular immunotherapy making cancer a chronic disease

  • How and why off-the-shelf?
  • Why are NK-cells important in cancer treatments?
  • Cancer management a viable option?
last published: 04/Jun/20 08:25 GMT

back to speakers